International recognition continues to accumulate for Jim Allison, Ph.D., for opening up an entirely new way to treat cancer by freeing the immune system to attack the disease.
Allison, MD Anderson’s chair of Immunology, will receive the inaugural Sjöberg Prize from the Sjöberg Foundation and the Royal Swedish Academy of Sciences on March 31 at the academy’s annual meeting in Stockholm. The foundation was launched last year by...
Melanoma patients’ response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies...
When triple-negative breast cancer is still in its earliest, pre-cancerous stages, the tumor suppressor miRNA-29c becomes progressively deactivated...
Researchers have identified a gatekeeper protein that prevents pancreatic cancer cells from transitioning into a particularly aggressive cell type and also found therapies capable of thwarting those cells when the gatekeeper is depleted.
A team from MD Anderson describes in the journal Nature a series of preclinical experiments using patient-derived tumor xenografts (PDXs) and mouse models that point to potential treatments...
A new study from MD Anderson finds that women with early-stage breast cancer who had an intermediate risk recurrence score (RS)...
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic...
Next-generation cyclin dependent kinase 2/9 (CDK2/9) inhibitors offer a new way to kill lung cancer while doing minimal harm to normal cells...
UBE20, a gene found on chromosome 17, may play a role in breast and prostate tumor formation, MD Anderson researchers found in a recent study...
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...
Cyclin E, a protein important for DNA replication, is present in various forms of cancer in high levels. Overexpression of cyclin E correlates...